<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878731</url>
  </required_header>
  <id_info>
    <org_study_id>B7841010</org_study_id>
    <nct_id>NCT04878731</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia</brief_title>
  <official_title>A PHASE 1, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, NON-CONTROLLED MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF A SINGLE SUBCUTANEOUS DOSE OF PF-06741086 IN CHINESE ADULT PARTICIPANTS WITH SEVERE HEMOPHILIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study will be a single-arm, open-label, non-randomized, non-controlled&#xD;
      investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of&#xD;
      PF-06741086 in Chinese adult participants with severe hemophilia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2021</start_date>
  <completion_date type="Actual">August 10, 2021</completion_date>
  <primary_completion_date type="Actual">August 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants by severity and causal relationship of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Day 1 up to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants by magnitude of abnormal laboratory findings</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with changes from baseline in vital sign</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>blood pressure, pulse rate, temperature and respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with changes from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants with changes from baseline in physical examination</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants by severity and causal relationship of injection site reactions</measure>
    <time_frame>Day 1 up to Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants of withdrawals due to TEAE</measure>
    <time_frame>Day 1 up to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma PF 06741086 concentrations</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak or maximum observed concentration (Cmax)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for Cmax (Tmax)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to last quantifiable concentration (AUClast)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration time curve from time 0 to infinity (AUCinf)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t 1/2)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue factor pathway inhibitor concentrations (TFPI total and free)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombin generation lag time</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin fragment 1+2 (PF1+2)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dilute prothrombin time (dPT)</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants of anti drug antibody (ADA) production against PF-06741086</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants of neutralizing antibody (NAb) production against PF-06741086</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>Immunogenicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak thrombin generation</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endogenous thrombin generation potential</measure>
    <time_frame>Day1 up to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Severe Hemophilia</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06741086 300mg subcutaneous(SC)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>single dose SC injection of 300 mg PF-06741086</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be male and 18 to &lt;75 years of age with a minimum body weight of 30&#xD;
             kg at screening.&#xD;
&#xD;
          -  Participants with a diagnosis of severe hemophilia A or B (FVIII or FIX activity &lt;1%,&#xD;
             respectively)&#xD;
&#xD;
          -  Participants without inhibitor must also meet the following criteria:&#xD;
&#xD;
               -  No detectable or documented history of inhibitors&#xD;
&#xD;
               -  Participants with on-demand treatment regimen with ≥6 acute bleeding episodes&#xD;
                  (spontaneous or traumatic) that required coagulation factor infusion during the 4&#xD;
                  months period prior to enrollment and willing to continue to receive on demand&#xD;
                  treatment during the study.&#xD;
&#xD;
          -  Participants with Inhibitor must also meet the following criteria:&#xD;
&#xD;
               -  Documentation of current high titer inhibitor (≥5 BU/mL) or current low titer&#xD;
                  inhibitor (&lt;5 BU/mL) refractory to FVIII or FIX replacement and with FVIII or FIX&#xD;
                  recovery &lt;60% of expected within previous 4 months prior to screening.&#xD;
&#xD;
               -  Participants with on-demand treatment regimen with ≥6 bleeding episodes&#xD;
                  (spontaneous and/or traumatic) necessitating treatment with bypass factor for at&#xD;
                  least 4 months prior to screening and willing to continue to receive on-demand&#xD;
                  treatment during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current treatment for and/or history of coronary artery diseases, venous&#xD;
             or arterial thrombosis or ischemic disease&#xD;
&#xD;
          -  Known planned surgical procedure during the planned study period.&#xD;
&#xD;
          -  Known hemostatic defect other than hemophilia A or B.&#xD;
&#xD;
          -  Abnormal renal or hepatic function&#xD;
&#xD;
          -  Current unstable liver or biliary disease&#xD;
&#xD;
          -  Abnormal hematologic parameters&#xD;
&#xD;
          -  Abnormal coagulation activity&#xD;
&#xD;
          -  Other acute or chronic medical or psychiatric condition or laboratory abnormality that&#xD;
             may increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator.&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt;450 msec for male participants or QTc &gt;480 msec in&#xD;
             participants with bundle branch block.&#xD;
&#xD;
          -  Individuals with hypersensitivity or an allergic reaction to hamster protein or other&#xD;
             components of the study intervention.&#xD;
&#xD;
          -  A positive urine drug screen&#xD;
&#xD;
          -  Current routine prophylaxis with bypassing agent or non coagulation factor-replacement&#xD;
             therapy (eg, emicizumab)&#xD;
&#xD;
          -  Regular, concomitant therapy with immunomodulatory drugs&#xD;
&#xD;
          -  Ongoing or planned use of immune tolerance induction or prophylaxis with FVIII or FIX&#xD;
             replacement during the study.&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) within 30 days (or as&#xD;
             determined by local requirements) or 5 half-lives prior to study entry and/or during&#xD;
             study participation.&#xD;
&#xD;
          -  CD4 cell count ≤200/uL if human immunodeficiency virus (HIV)-positive&#xD;
&#xD;
          -  Baseline ECG that demonstrates clinically relevant abnormalities that may affect&#xD;
             participant safety or interpretation of study results.&#xD;
&#xD;
          -  Investigator site staff members directly involved in the conduct of the study and&#xD;
             their family members, site staff members otherwise supervised by the investigator, or&#xD;
             participants who are Pfizer employees, including their family members, directly&#xD;
             involved in the conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Hematology, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7841010</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 3, 2021</last_update_submitted>
  <last_update_submitted_qc>September 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

